MedTrace Logo

Combined Antioxidant Therapy for Acute Myocardial Infarction

NCT07776288 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-08-20

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a combined antioxidant therapy (CAT) can reduce heart damage caused by the return of blood flow after blocked arteries are reopened in adults with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). It will also learn about the safety of this treatment. The main questions it aims to answer are:

1. Does combined antioxidant therapy lower infarct size, measured by cardiac magnetic resonance imaging (CMR), compared with placebo?
2. Does combined antioxidant therapy improve heart function, blood biomarkers of heart injury, and short-term clinical outcomes?
3. What problems do participants have when receiving the therapy?

Researchers will compare CAT to placebo (a look-alike infusion with no active drug) to see if the treatment lowers infarct size after STEMI.

Participants will:

* Be randomly assigned to receive either CAT or placebo
* Receive the study infusion before and during primary PCI, in addition to standard treatment for STEMI
* Have blood tests to measure heart injury, oxidative stress, inflammation, and drug levels
* Undergo cardiac magnetic resonance imaging about 3 to 7 days after STEMI.
* Be followed for clinical outcomes and safety for 30 days.

Conditions

  • Acute Myocardial Infarction (AMI)
  • ST Elevation (STEMI) Myocardial Infarction
  • Reperfusion Injuries, Myocardial

Interventions

DRUG

Combined antioxidant therapy

Combined Antioxidant Therapy consisting of ascorbate, N-acetylcysteine and deferoxamine

DRUG

Placebo

Matching placebo infusion administered before reperfusion and during primary PCI.

Sponsors & Collaborators

  • Hospital San Juan de Dios,Chile

    collaborator OTHER

  • University of Chile

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-01-31
Completion
2027-12-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776288 on ClinicalTrials.gov